Dodge & Cox’s AstraZeneca AZN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $10.6M | Sell |
55,949
-1,525
| -3% | -$287K | 0.01% | 129 |
|
|
2026
Q1 | $11.3M | Sell |
57,474
-3,048
| -5% | -$588K | 0.01% | 128 |
|
|
2025
Q4 | $11.1M | Sell |
60,522
-8,222
| -12% | -$1.44M | 0.01% | 126 |
|
|
2025
Q3 | $10.5M | Hold |
68,744
| – | – | 0.01% | 126 |
|
|
2025
Q2 | $9.61M | Buy |
68,744
+674
| +1% | +$94.5K | 0.01% | 127 |
|
|
2025
Q1 | $10M | Sell |
68,070
-3,785
| -5% | -$548K | 0.01% | 119 |
|
|
2024
Q4 | $9.42M | Sell |
71,855
-2,663
| -4% | -$373K | 0.01% | 121 |
|
|
2024
Q3 | $11.6M | Sell |
74,518
-375
| -0.5% | -$60.5K | 0.01% | 118 |
|
|
2024
Q2 | $11.7M | Sell |
74,893
-2,750
| -4% | -$414K | 0.01% | 118 |
|
|
2024
Q1 | $10.5M | Sell |
77,643
-195
| -0.3% | -$25.8K | 0.01% | 116 |
|
|
2023
Q4 | $10.5M | Sell |
77,838
-825
| -1% | -$107K | 0.01% | 117 |
|
|
2023
Q3 | $10.7M | Sell |
78,663
-19,625
| -20% | -$2.68M | 0.01% | 115 |
|
|
2023
Q2 | $14.1M | Sell |
98,288
-13,425
| -12% | -$1.98M | 0.01% | 108 |
|
|
2023
Q1 | $15.5M | Sell |
111,713
-42,450
| -28% | -$5.71M | 0.01% | 108 |
|
|
2022
Q4 | $20.9M | Sell |
154,163
-39,020
| -20% | -$4.89M | 0.01% | 104 |
|
|
2022
Q3 | $21.2M | Sell |
193,183
-58,062
| -23% | -$7.37M | 0.02% | 103 |
|
|
2022
Q2 | $33.2M | Sell |
251,245
-152,168
| -38% | -$20M | 0.02% | 99 |
|
|
2022
Q1 | $53.5M | Sell |
403,413
-5,535
| -1% | -$664K | 0.03% | 95 |
|
|
2021
Q4 | $47.6M | Sell |
408,948
-12,985
| -3% | -$1.53M | 0.03% | 95 |
|
|
2021
Q3 | $50.7M | Sell |
421,933
-15,080
| -3% | -$1.76M | 0.03% | 90 |
|
|
2021
Q2 | $52.4M | Sell |
437,013
-8,125
| -2% | -$891K | 0.03% | 87 |
|
|
2021
Q1 | $44.3M | Sell |
445,138
-1,212,448
| -73% | -$122M | 0.03% | 88 |
|
|
2020
Q4 | $166M | Sell |
1,657,586
-5,753,087
| -78% | -$609M | 0.13% | 83 |
|
|
2020
Q3 | $812M | Sell |
7,410,673
-1,977,209
| -21% | -$220M | 0.74% | 50 |
|
|
2020
Q2 | $993M | Sell |
9,387,882
-5,553,637
| -37% | -$574M | 0.91% | 43 |
|
|
2020
Q1 | $1.33B | Sell |
14,941,519
-4,295,946
| -22% | -$404M | 1.44% | 28 |
|
|
2019
Q4 | $1.92B | Sell |
19,237,465
-5,437,105
| -22% | -$512M | 1.47% | 30 |
|
|
2019
Q3 | $2.2B | Buy |
24,674,570
+6,089
| +0% | +$528K | 1.81% | 24 |
|
|
2019
Q2 | $2.04B | Sell |
24,668,481
-38,620
| -0.2% | -$3.03M | 1.65% | 27 |
|
|
2019
Q1 | $2B | Sell |
24,707,101
-51,100
| -0.2% | -$4.03M | 1.64% | 26 |
|
|
2018
Q4 | $1.88B | Sell |
24,758,201
-811,954
| -3% | -$63.4M | 1.72% | 23 |
|
|
2018
Q3 | $2.02B | Sell |
25,570,155
-817,250
| -3% | -$61.8M | 1.55% | 27 |
|
|
2018
Q2 | $1.85B | Sell |
26,387,405
-877,685
| -3% | -$63.1M | 1.48% | 27 |
|
|
2018
Q1 | $1.91B | Sell |
27,265,090
-1,000,400
| -4% | -$69.3M | 1.54% | 26 |
|
|
2017
Q4 | $1.96B | Buy |
28,265,490
+165,401
| +0.6% | +$11.2M | 1.52% | 27 |
|
|
2017
Q3 | $1.9B | Sell |
28,100,089
-234,636
| -0.8% | -$14.8M | 1.53% | 27 |
|
|
2017
Q2 | $1.93B | Sell |
28,334,725
-118,525
| -0.4% | -$7.74M | 1.63% | 26 |
|
|
2017
Q1 | $1.77B | Buy |
28,453,250
+3,646,456
| +15% | +$212M | 1.51% | 26 |
|
|
2016
Q4 | $1.36B | Buy |
24,806,794
+3,711,807
| +18% | +$211M | 1.2% | 33 |
|
|
2016
Q3 | $1.39B | Buy |
21,094,987
+4,828,625
| +30% | +$316M | 1.3% | 33 |
|
|
2016
Q2 | $982M | Buy |
16,266,362
+3,241,537
| +25% | +$188M | 0.97% | 38 |
|
|
2016
Q1 | $734M | Buy |
13,024,825
+7,136,259
| +121% | +$429M | 0.72% | 49 |
|
|
2015
Q4 | $400M | Buy |
+5,888,566
| New | +$386M | 0.39% | 62 |
|
Other funds holding AZN
EP
IA
Dodge & Cox's AZN Position: Q2 2026 in Review
Dodge & Cox reduced its AstraZeneca (AZN) stake by 2.7% in Q2 2026, selling an estimated $287K and leaving 55,949 shares worth $10.6M. The position accounts for 0.01% of the portfolio, ranked #129.
Dodge & Cox first reported a position in AZN in Q4 2015 and has held it in 43 quarters since. The position peaked at $2.2B in Q3 2019. 1,498 funds tracked by Wall St. Rank hold AZN as of Q2 2026.
- Dodge & Cox held 55,949 shares of AstraZeneca worth $10.6M as of Q2 2026.
- Dodge & Cox sold 1,525 AstraZeneca shares in Q2 2026, an estimated $287K.
- AstraZeneca made up 0.01% of Dodge & Cox's portfolio in Q2 2026, its #129 holding.
- Dodge & Cox first reported a position in AstraZeneca in Q4 2015 and has held it in 43 quarters since.
- Dodge & Cox's AstraZeneca position peaked at $2.2B in Q3 2019.
- 1,498 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2026.
Based on Dodge & Cox's 13F filing for Q2 2026, filed 13 Aug 2026.